Novartis Builds On Its Legacy With Scemblix Approval For CML
Executive Summary
US FDA approval means a new commercial opportunity in CML, where despite the success of older medicines, patients still fail on therapy.
You may also be interested in...
Novartis Poised To Grow Despite $9bn In LOEs Coming, CEO Says
CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.
Novartis Novel STAMP Inhibitor Passes First Phase III Test In CML
Phase III data for asciminib suggest it could provide a new avenue of therapy for chronic myeloid leukemia patients who are running out of treatment options.
Here Comes Sun’s US Cost-Saving Gleevec Generic
India’s Sun Pharma has launched its generic version of Novartis' blockbuster anticancer Gleevec in the US at savings of around 30%, putting the spotlight on the specialty segment which is probably, for the first time, witnessing genericization of such a high cost therapy.